PET/CT mit Ga-68-DOTATOC bei neuroendokrinen Tumoren: Ist ein zusätzliches Knochenszintigramm hilfreich?

Aschoff, Philip; Oeksuez, Mehmet; Kemke, M.; Zhernosekov, Konstantin; Jennewein, M.; Roesch, Frank; Bihl, H.

doi:10.1055/s-2005-867691

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…56 DTPA has been successfully used as the BFC in the FDAapproved SPECT agent OctreoScan TM ( 111 In-DTPA-octreotide), a somatostatin-targeting peptide-conjugate used for imaging neuroendocrine tumors. 205,206 DTPA has also been successfully used with radiometals such as 64 Cu, 111 In, 177 Lu, and 86/90 Y, but has been made redundant by more stable new chelators like DOTA, NOTA, and CHX-A 00 -DTPA (Table 7). 56,161 The shortcomings of DTPA have been improved through design of novel derivatives, such as the DTPA derivatives 1B4M-DTPA (Tiuxetan) and CHX-A 00 -DTPA.…”

Section: Diamsar and Derivativesmentioning

confidence: 99%

Matching chelators to radiometals for radiopharmaceuticals

2014

View full text Add to dashboard Cite

Radiometals comprise many useful radioactive isotopes of various metallic elements. When properly harnessed, these have valuable emission properties that can be used for diagnostic imaging techniques, such as single photon emission computed tomography (SPECT, e.g.(67)Ga, (99m)Tc, (111)In, (177)Lu) and positron emission tomography (PET, e.g.(68)Ga, (64)Cu, (44)Sc, (86)Y, (89)Zr), as well as therapeutic applications (e.g.(47)Sc, (114m)In, (177)Lu, (90)Y, (212/213)Bi, (212)Pb, (225)Ac, (186/188)Re). A fundamental critical component of a radiometal-based radiopharmaceutical is the chelator, the ligand system that binds the radiometal ion in a tight stable coordination complex so that it can be properly directed to a desirable molecular target in vivo. This article is a guide for selecting the optimal match between chelator and radiometal for use in these systems. The article briefly introduces a selection of relevant and high impact radiometals, and their potential utility to the fields of radiochemistry, nuclear medicine, and molecular imaging. A description of radiometal-based radiopharmaceuticals is provided, and several key design considerations are discussed. The experimental methods by which chelators are assessed for their suitability with a variety of radiometal ions is explained, and a large selection of the most common and most promising chelators are evaluated and discussed for their potential use with a variety of radiometals. Comprehensive tables have been assembled to provide a convenient and accessible overview of the field of radiometal chelating agents.

show abstract

Section: Diamsar and Derivativesmentioning

confidence: 99%

Matching chelators to radiometals for radiopharmaceuticals

2014

View full text Add to dashboard Cite

show abstract

“…In two recent abstracts Aschoff et al (Aschoff et al 2005a(Aschoff et al , 2005b) concluded that the sensitivity of 68 Ga-DOTA-TOC in neuroendocrine tumours exceeded that of OctreoScan; in 24 of 36 patients additional lesions were found (Fig. 15).…”

Section: Patient Studiesmentioning

confidence: 94%

68Ga-PET Radiopharmacy: A Generator-Based Alternative to 18F-Radiopharmacy

Maecke

André

Ernst Schering Research Foundation Workshop

View full text Add to dashboard Cite

PET/CT mit Ga-68-DOTATOC bei neuroendokrinen Tumoren: Ist ein zusätzliches Knochenszintigramm hilfreich?

Cited by 2 publications

References 0 publications

Matching chelators to radiometals for radiopharmaceuticals

Matching chelators to radiometals for radiopharmaceuticals

68Ga-PET Radiopharmacy: A Generator-Based Alternative to 18F-Radiopharmacy

Contact Info

Product

Resources

About